In an era of widespread genetic sequencing, the ability to edit and alter an organism’s DNA is a powerful way to explore the information within and how it guides biological function.
A paper from the University of Wisconsin-Madison in the August issue of the journal GENETICS takes genome editing to a new level in fruit flies, demonstrating a remarkable level of fine control and, importantly, the transmission of those engineered genetic changes across generations.
Both features are key for driving the utility and spread of an approach that promises to give researchers new insights into the basic workings of biological systems, including embryonic development, nervous system function, and the understanding of human disease.
“Genome engineering allows you to change gene function in a very targeted way, so you can probe function at a level of detail” that wasn’t previously possible, says Melissa Harrison, an assistant professor of biomolecular chemistry in the UW-Madison School of Medicine and Public Health and one of the three senior authors of the new study.
Disrupting individual genes has long been used as a way to study their roles in biological function and disease. The new approach, based on molecules that drive a type of bacterial immune response, provides a technical advance that allows scientists to readily engineer genetic sequences in very detailed ways, including adding or removing short bits of DNA in chosen locations, introducing specific mutations, adding trackable tags, or changing the sequences that regulate when or where a gene is active.
The approach used in the new study, called the CRISPR RNA/Cas9 system, has developed unusually fast. First reported just one year ago by scientists at the Howard Hughes Medical Institute and University of California, Berkeley, it has already been applied to most traditional biological model systems, including yeast, zebrafish, mice, the nematode C. elegans, and human cells. The Wisconsin paper was the first to describe it in fruit flies and to show that the resulting genetic changes could be passed from one generation to the next.
“There was a need in the community to have a technique that you could use to generate targeted mutations,” says Jill Wildonger, a UW-Madison assistant professor of biochemistry and another senior author of the paper. “The need was there and this was the technical advance that everyone had been waiting for.”
“The reason this has progressed so quickly is that many researchers — us included — were working on other, more complicated, approaches to do exactly the same thing when this came out,” adds genetics assistant professor Kate O’Connor-Giles, the third senior author. “This is invaluable for anyone wanting to study gene function in any organism and it is also likely to be transferable to the clinical realm and gene therapy.”
The CRISPR RNA/Cas9 system directs a DNA-clipping enzyme called Cas9 to snip the DNA at a targeted sequence. This cut then stimulates the cell’s existing DNA repair machinery to fill in the break while integrating the desired genetic tweaks. The process can be tailored to edit down to the level of a single base pair — the rough equivalent of changing a single letter in a document with a word processor.
The broad applicability of the system is aided by a relatively simple design that can be customized through creation of a short RNA sequence to target a specific sequence in the genome to generate the desired changes. Previous genome editing methods have relied on making custom proteins, which is costly and slow.
“This is so readily transferable that it’s highly likely to enable gene knockout and other genome modifications in any organism,” including those that have not previously been used for laboratory work, says O’Connor-Giles. “It’s going to turn non-model organisms into genetic model organisms.”
That ease may also pay off in the clinic. “It can be very difficult and time-consuming to generate models to study all the gene variants associated with human diseases,” says Wildonger. “With this genome editing approach, if we work in collaboration with a clinician to find [clinically relevant] mutations, we can rapidly translate these into a fruit fly model to see what’s happening at the cellular and molecular level.”
The Latest Bing News on:
Genome editing
- CTCRI to use genome editing to develop industry-friendly tapioca varietieson May 10, 2024 at 6:56 am
in Thiruvananthapuram has embarked on a ₹4 crore research project for developing tapioca varieties with waxy or high-amylose starches that are useful in industry with the help of CRISPR-Cas9 genome ...
- CRISPR edits fail to cure HIV patients in early teston May 10, 2024 at 6:40 am
Excision BioTherapeutics reported Friday that an early trial failed to cure HIV patients, but the company plans to try again with a more efficient editing treatment.
- PhD student wins 2024 Illinois Innovation Award for work in ALSon May 10, 2024 at 5:00 am
A University of Illinois PhD student in bioengineering won a $20,000 Innovation Award for her work on next-generation therapies for ALS.
- Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editingon May 9, 2024 at 7:00 am
NDAQ:SGMO) Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing ...
- Editas Medicine’s Innovative In Vivo Gene Editing Approach and Positive Clinical Trial Prospects Bolster Buy Ratingon May 9, 2024 at 3:26 am
Editas Medicine (EDIT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
- Team develops an epigenome editing toolkit to dissect the mechanisms of gene regulationon May 8, 2024 at 5:00 pm
The set of epigenetic modifications of a cell's genome is referred to as the epigenome. In a study just published in Nature Genetics, scientists from the Hackett Group at EMBL Rome have developed a ...
- An epigenome editing toolkit to dissect the mechanisms of gene regulationon May 8, 2024 at 5:00 pm
A study from the Hackett group at EMBL Rome led to the development of a powerful epigenetic editing technology. The system unlocks the ability to precisely program chromatin modifications at any ...
- ASGCT 2024: Mammoth Sizes Up Genome Editing Opportunitieson May 8, 2024 at 11:16 am
We catch up with Mammoth Biosciences CSO Lucas Harrington after his ASGCT presentation. Harrington lays out his company's big plans in developing a range of therapeutic options using miniature Cas ...
- Gene Editing for Inherited Form of Blindness Shows Promise in Phase I/II Trialon May 6, 2024 at 10:01 am
CRISPR gene editing leads to improvements in vision for people with inherited blindness, a recent clinical trial shows.
- CRIPSR gene editing leads to improvements in vision for people with inherited blindness, clinical trial showson May 6, 2024 at 9:14 am
Results of a phase 1/2 clinical trial of CRISPR gene editing in 14 individuals with a form of inherited blindness show that the treatment is safe and led to measurable improvements in 11 of the ...
The Latest Google Headlines on:
Genome editing
[google_news title=”” keyword=”Genome editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
CRISPR RNA/Cas9
- PhD student wins 2024 Illinois Innovation Award for work in ALSon May 10, 2024 at 5:00 am
A University of Illinois PhD student in bioengineering won a $20,000 Innovation Award for her work on next-generation therapies for ALS.
- Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Icebergon May 9, 2024 at 6:32 am
Crispr Therapeutics AG shows potential for future earnings with its gene editing therapy Casgevy, offering treatment for various diseases. Read more here.
- Controversial scientist says he’ll use gene editing to end HIV & Alzheimer’son May 8, 2024 at 3:18 pm
Right now, U.S. law and universal medical ethics state that gene editing should only be used on laboratory animals, in order to test whether the technology might be safe for humans. But if He is ...
- CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approachon May 8, 2024 at 4:00 am
ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma - - Expands pipeline ...
- CRISPR Enzyme Found in Metagenomic Study Is Tiny, Yet Active and Preciseon May 6, 2024 at 6:30 pm
Metagenomic study uncovers previously uncharacterized Cas9 nucleases, including CoCas9, which is compact, but still active and precise.
- CRISPR gene editing trial treats inherited blindnesson May 6, 2024 at 11:27 am
Researchers have used a CRISPR-Cas9 tool to restore vision in adults and children with congenital blindness. The researchers said they hoped to soon cure the condition.
- Cutting-Edge CRISPR: Princeton Researchers Develop a More Precise Gene-Editing Toolon May 5, 2024 at 5:07 am
Princeton scientists make a major improvement to a CRISPR-based gene-editing tool called “prime editing.” Through years of engineering gene-editing systems, researchers have developed a suite of tools ...
- A New Delivery System Offers Hope for Cystic Fibrosison May 1, 2024 at 7:52 am
CRISPR-carrying lipid nanoparticles enabled researchers to correct a rare nonsense mutation in the lungs of a cystic fibrosis mouse model.
- Invest In A Revolutionary Gene Therapy With CRISPR Therapeuticson April 30, 2024 at 10:25 am
CRISPR Therapeutics' Casgevy could generate significant shareholder value if proven to be successful. Learn why I am highly bullish on CRSP stock.
- CRISPR Edits RNA in Living Cellson April 29, 2024 at 5:00 pm
but that applying similar technology to RNA is unprecedented. DNA editing uses a CRISPR-associated protein called Cas9, while editing RNA requires the use of a different CRISPR system, called type-III ...
The Latest Google Headlines on:
CRISPR RNA/Cas9
[google_news title=”” keyword=”CRISPR RNA/Cas9″ num_posts=”10″ blurb_length=”0″ show_thumb=”left”]